AVRO AVROBIO Inc

Price (delayed)

$1.3

Market cap

$57.95M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.09

Enterprise value

-$46.43M

AVROBIO's vision is to bring personalized gene therapy to the world. The company aims to prevent, halt or reverse disease throughout the body with a single dose of gene therapy ...

Highlights
AVRO's net income has surged by 96% year-on-year and by 25% since the previous quarter
The EPS has surged by 96% year-on-year and by 31% since the previous quarter
AVROBIO's equity has decreased by 16% from the previous quarter but it has increased by 4.9% YoY

Key stats

What are the main financial stats of AVRO
Market
Shares outstanding
44.57M
Market cap
$57.95M
Enterprise value
-$46.43M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.56
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$5.5M
EBITDA
-$222,000
Free cash flow
-$77.64M
Per share
EPS
-$0.09
Free cash flow per share
-$1.74
Book value per share
$2.31
Revenue per share
$0
TBVPS
$2.48
Balance sheet
Total assets
$110.52M
Total liabilities
$7.66M
Debt
$1.75M
Equity
$102.86M
Working capital
$101.61M
Liquidity
Debt to equity
0.02
Current ratio
14.44
Quick ratio
14.04
Net debt/EBITDA
470.15
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-3.8%
Return on equity
-4.6%
Return on invested capital
-80.4%
Return on capital employed
-5.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AVRO stock price

How has the AVROBIO stock price performed over time
Intraday
0.78%
1 week
0%
1 month
-2.26%
1 year
-23.08%
YTD
-4.41%
QTD
-4.41%

Financial performance

How have AVROBIO's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$5.4M
Net income
-$4.09M
Gross margin
N/A
Net margin
N/A
AVRO's net income has surged by 96% year-on-year and by 25% since the previous quarter
AVRO's operating income has surged by 95% year-on-year

Growth

What is AVROBIO's growth rate over time

Valuation

What is AVROBIO stock price valuation
P/E
N/A
P/B
0.56
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 96% year-on-year and by 31% since the previous quarter
AVRO's price to book (P/B) is 69% less than its 5-year quarterly average of 1.8 and 7% less than its last 4 quarters average of 0.6
AVROBIO's equity has decreased by 16% from the previous quarter but it has increased by 4.9% YoY

Efficiency

How efficient is AVROBIO business performance
AVROBIO's ROE has soared by 94% YoY and by 27% from the previous quarter
The return on assets has surged by 94% year-on-year and by 22% since the previous quarter
The ROIC has soared by 91% YoY but it has decreased by 47% from the previous quarter

Dividends

What is AVRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AVRO.

Financial health

How did AVROBIO financials performed over time
AVROBIO's quick ratio has soared by 95% YoY and by 31% from the previous quarter
AVRO's current ratio has soared by 85% YoY and by 31% QoQ
AVRO's debt is 98% smaller than its equity
The debt to equity has shrunk by 88% YoY
AVRO's debt has dropped by 88% year-on-year and by 27% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.